Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E–mutant rectal cancer with bowel obstruction
Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups
FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
The <scp>CAR‐HEMATOTOX</scp> score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory <scp>MCL</scp>
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy